Type 2 diabetes — once considered a slow and silent epidemic — is now at the center of one of the most intense healthcare revolutions of our time. With more than 500 million people affected globally, the disease has driven pharmaceutical companies, biotech startups, and tech giants into a high-stakes race to find better, smarter, and longer-lasting solutions. And the payoff?...